Biochimica et Biophysica Acta-Reviews on Cancer

Papers
(The TQCC of Biochimica et Biophysica Acta-Reviews on Cancer is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Tumour cell-induced platelet aggregation in breast cancer: Scope of metal nanoparticles360
Microbial influence on triggering and treatment of host cancer: An intestinal barrier perspective244
Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique?178
Advances in epigenetic modifications and cervical cancer research160
Modeling bladder cancer in the laboratory: Insights from patient-derived organoids152
TSPAN1, a novel tetraspanin member highly involved in carcinogenesis and chemoresistance148
miRNAs and androgen deprivation therapy for prostate cancer121
The interaction of SET and protein phosphatase 2A as target for cancer therapy101
Nutrition and dietary restrictions in cancer prevention100
Reflections on drug resistance to KRAS inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment97
Uveal melanoma modeling in mice and zebrafish91
ESR1 activating mutations: From structure to clinical application89
Progress and challenges of immunotherapy in triple-negative breast cancer85
Decoding the role of FOXP3 in esophageal cancer: Underlying mechanisms and therapeutic implications76
Prostate cancer: Molecular aspects, consequences, and opportunities of the multifocal nature75
Targeting lipid metabolism in cancer metastasis71
Transcription factors in glioblastoma – Molecular pathogenesis and clinical implications68
In what area of biology has a “new” type of cell death been discovered?67
Extracellular vesicles in cancer therapy: Roles, potential application, and challenges65
Epigenetic changes associated with Bacillus Calmette-Guerin (BCG) treatment in bladder cancer60
Dual perspective on autophagy in glioma: Detangling the dichotomous mechanisms of signaling pathways for therapeutic insights60
Insights into the role of connexins and specialized intercellular communication pathways in breast cancer: Mechanisms and applications60
Contribution of CXCR3-mediated signaling in the metastatic cascade of solid malignancies55
Biomarkers in high grade serous ovarian cancer54
S100A8 and S100A9 in Cancer52
Long non-coding RNAs: Fundamental regulators and emerging targets of cancer stem cells50
Advances and prospects of mRNA vaccines in cancer immunotherapy49
Mitochondrial metabolism in laryngeal cancer: Therapeutic mechanisms and prospects48
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting46
Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors45
Prognostic features of the tumour microenvironment in oesophageal adenocarcinoma45
The interplay of obesity, microbiome dynamics, and innovative anti-obesity strategies in the context of endometrial cancer progression and therapeutic approaches45
Multiple therapeutic approaches of glioblastoma multiforme: From terminal to therapy45
Targeting Cdc20 for cancer therapy44
Recent insights into RNA m5C methylation modification in hepatocellular carcinoma44
Multifaceted roles of neutrophils in tumor microenvironment44
Small non-coding RNAs and pancreatic ductal adenocarcinoma: Linking diagnosis, pathogenesis, drug resistance, and therapeutic potential43
Multiple impacts of Naa10p on cancer progression: Molecular functions and clinical prospects42
Interleukin-21 as an adjuvant in cancer immunotherapy: Current advances and future directions42
Long non-coding RNAs: A view to kill ovarian cancer42
Editorial Board41
Epithelial-Mesenchymal Transition in Cancer: A Focus on Itraconazole, a Hedgehog Inhibitor40
Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies40
An overview of BAP1 biological functions and current therapeutics39
Nondiploid cancer cells: Stress, tolerance and therapeutic inspirations39
Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis38
Vagus innervation in the gastrointestinal tumor: Current understanding and challenges38
Matrisomics: Beyond the extracellular matrix for unveiling tumor microenvironment38
Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: A systematic review and meta-analysis38
Current advances in comprehensive omics data mining for oncology and cancer research38
Abnormal metabolism in hepatic stellate cells: Pandora's box of MAFLD related hepatocellular carcinoma37
Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low36
Intestinal multicellular organoids to study colorectal cancer36
Refinement of safety and efficacy of anti-cancer chemotherapeutics by tailoring their site-specific intracellular bioavailability through transporter modulation36
CD8+ T-cell exhaustion: Impediment to triple-negative breast cancer (TNBC) immunotherapy35
The Pleiotropic role, functions and targeted therapies of LIF/LIFR axis in cancer: Old spectacles with new insights34
Cross talk between autophagy and oncogenic signaling pathways and implications for cancer therapy34
Ubiquitination/de-ubiquitination: A promising therapeutic target for PTEN reactivation in cancer34
In vitro anticancer properties of anthocyanins: A systematic review34
Implications of viral infection in cancer development34
Mesenchymal stem cells in glioblastoma therapy and progression: How one cell does it all34
Cellular functions, molecular signalings and therapeutic applications: Translational potential of deubiquitylating enzyme USP9X as a drug target in cancer treatment33
Focus on mast cells in the tumor microenvironment: Current knowledge and future directions33
ASPORIN: A root of the matter in tumors and their host environment33
Unveiling the potential of gene editing techniques in revolutionizing Cancer treatment: A comprehensive overview31
The emerging roles of dual-specificity phosphatases and their specific characteristics in human cancer31
A role for RIO kinases in the crosshair of cancer research and therapy31
Platinum-based systematic therapy in triple-negative breast cancer31
Muscle-to-tumor crosstalk: The effect of exercise-induced myokine on cancer progression30
Advances in clinical immunotherapy for gastric cancer30
HOXA1, a breast cancer oncogene29
Schwann cells and enteric glial cells: Emerging stars in colorectal cancer29
Exploring the gut microbiome: A potential biomarker for cancer diagnosis, prognosis, and therapy29
Overview of splicing variation in ovarian cancer29
Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma29
Exosomal non-coding RNAs (ncRNAs) as potential biomarkers in tumor early diagnosis29
Dual role of Snail1 as transcriptional repressor and activator28
Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages28
Strategies for studying immune and non-immune human and canine mammary gland cancer tumour infiltrate28
New target DDR1: A “double-edged sword” in solid tumors28
Colorectal cancer: Metabolic interactions reshape the tumor microenvironment28
Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer28
RUNX1 and cancer27
A novel approach to reducing disparities in health outcomes by enhancing interpretation of cancer clinical trials for underrepresented patient groups27
Role of F-box proteins in human upper gastrointestinal tumors27
Research progress on the regulatory role of lactate and lactylation in tumor microenvironment27
Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors27
Carbonic anhydrase IX: An atypical target for innovative therapies in cancer27
A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors27
USP7 - a crucial regulator of cancer hallmarks27
SNARE proteins: Core engines of membrane fusion in cancer26
Proteomics of post-translational modifications in colorectal cancer: Discovery of new biomarkers26
Interleukin-1 signaling in solid organ malignancies26
Potentially diagnostic and prognostic roles of piRNAs/PIWIs in pancreatic cancer: A review26
Data-driven approaches to advance research and clinical care for pediatric cancer26
Stress granules dynamics and promising functions in pancreatic cancer26
Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers25
To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H325
Perspectives and mechanisms for targeting mitotic catastrophe in cancer treatment25
Scientific and clinical relevance of non-cellular tumor microenvironment components in ovarian cancer chemotherapy resistance25
Epigenetic regulation of cancer-associated fibroblast heterogeneity25
From resistance to resilience: Uncovering chemotherapeutic resistance mechanisms; insights from established models25
Keep your eyes peeled for long noncoding RNAs: Explaining their boundless role in cancer metastasis, drug resistance, and clinical application25
Augmentation of the EPR effect by mild hyperthermia to improve nanoparticle delivery to the tumor24
New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas24
Consequence of distinctive expression of MUC2 in colorectal cancers: How much is actually bad?23
A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer23
Keratin 1 as a cell-surface receptor in cancer23
The clinical significance and correlative signaling pathways of paired box gene 9 in development and carcinogenesis23
Emerging roles of PIWI-interacting RNAs (piRNAs) and PIWI proteins in head and neck cancer and their potential clinical implications23
A digital highway for data fluidity and data equity in precision medicine23
Reflecting on the cardiac toxicity in non-small cell lung cancer in the era of immune checkpoint inhibitors therapy combined with thoracic radiotherapy22
Research progress of mitochondria and cytoskeleton crosstalk in tumour development22
Understanding the role of DNA methylation in colorectal cancer: Mechanisms, detection, and clinical significance22
Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review22
Dual roles of human endogenous retroviruses in cancer progression and antitumor immune response22
Spatiotemporal heterogeneity and clinical challenge of pancreatic neuroendocrine tumors22
Machine Learning in Epigenomics: Insights into Cancer Biology and Medicine22
Histone deacetylase complexes: Structure, regulation and function22
Improving DCIS diagnosis and predictive outcome by applying artificial intelligence22
Expression and function of NF-Y subunits in cancer22
The correlation between gut and intra-tumor microbiota and PDAC: Etiology, diagnostics and therapeutics22
Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p5322
The neoantigens derived from transposable elements – A hidden treasure for cancer immunotherapy22
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents21
Editorial Board21
Finding the junction between claudins and endometrial carcinoma21
Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors21
The interplay between microbiome and host factors in pathogenesis and therapy of head and neck cancer21
Tumoral heterogeneity in neuroblastoma21
Centrosome amplification in cancer and cancer-associated human diseases21
Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives21
Role of the intratumoral microbiome in tumor progression and therapeutics implications20
Psychological intervention to treat distress: An emerging frontier in cancer prevention and therapy20
The signaling pathways regulated by KRAB zinc-finger proteins in cancer20
CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways20
B7-H3 regulates anti-tumor immunity and promotes tumor development in colorectal cancer20
Tumor microenvironment diversity and plasticity in cancer multidrug resistance20
βIII-tubulin overexpression in cancer: Causes, consequences, and potential therapies20
Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer20
Editorial Board19
Clinical and Molecular Attributes and Evaluation of Pancreatic Cystic Neoplasm19
Enhancing immune checkpoint blockade therapy of genitourinary malignancies by co-targeting PMN-MDSCs19
Thymic epithelial tumor medical treatment: A narrative review19
A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment19
Advances in glioma models using in vivo electroporation to highjack neurodevelopmental processes19
GSDM family and glioma19
Dietary and serum advanced glycation end-products and clinical outcomes in breast cancer19
Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?19
Advances in tuft cells, a chemosensory cell in sequential diseases of the pancreas19
Molecular and immune pathobiology of human angiosarcoma19
Cancer-associated fungi: An emerging powerful player in cancer immunotherapy19
The comparison of pathogenic role and mechanism of Kallistatin and PEDF in tumors19
Odors and cancer: Current status and future directions18
TERT promoter mutations in gliomas: Molecular roles in tumorigenesis, metastasis, diagnosis, prognosis, therapeutic targeting, and drug resistance18
Roles of K(H)SRP in modulating gene transcription throughout cancer progression: Insights from cellular studies to clinical perspectives18
Cyclin-dependent kinases in DNA damage response18
The role of exosomes in the tumour microenvironment on macrophage polarisation18
The role of TRIM25 in the occurrence and development of cancers and inflammatory diseases18
Protein induced by vitamin K absence or antagonist II: Experience to date and future directions18
The potential of TRP channels as new prognostic and therapeutic targets against prostate cancer progression18
0.1626501083374